PT-141 (Bremelanotide): Sexual Function Research

Research on the melanocortin-based peptide for libido and sexual health

Source: https://indexalabs.com/blog/pt-141-bremelanotide-sexual-function Abstract: PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. This guide covers its unique CNS-based mechanism and research applications in sexual function.

1. Overview

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist developed from Melanotan II. Unlike PDE5 inhibitors that work peripherally, PT-141 enhances sexual desire through central nervous system pathways. It is FDA-approved as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women.

2. Mechanisms of Action

2.1 MC3/MC4 Receptor Activation PT-141 activates melanocortin-3 and melanocortin-4 receptors in the hypothalamus.

2.2 Dopamine Pathways MC4R activation modulates dopaminergic pathways involved in sexual motivation.

2.3 Central vs. Peripheral Unlike Viagra/Cialis, PT-141 addresses desire, not just mechanical function.

2.4 Gender Applicability Research and approval includes both male and female applications.

3. Clinical Evidence

3.1 HSDD Trials Phase 3 trials led to FDA approval for female HSDD in 2019.

3.2 Male Erectile Function Earlier research examined effects in erectile dysfunction.

3.3 Onset and Duration Effects typically begin within 45 minutes and last several hours.

3.4 Safety Profile Nausea is the most common side effect; no cardiovascular contraindications like PDE5 inhibitors.

4. Research Protocols

4.1 Available Sizes PT-141 is available in 5mg vials.

4.2 Administration Subcutaneous injection approximately 45 minutes before desired effect.

4.3 Frequency Clinical trials limited use to no more than once every 24 hours.